| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514263310 | With perservative, stabilizer, or an additional active ingredient | 22 |
| 20080200484 | Pharmaceutical Compositions Comprising A Multifunctional Phosphodiesterase Inhibitor and An Adenosine Uptake Inhibitor - The present invention relates to pharmaceutical compositions comprising at least one multifunctional phosphodiesterase inhibitor (MPDEI) and at least one adenosine uptake inhibitor. The present invention also relates to compositions comprising cilostazol and dipyridamole and their use. | 08-21-2008 |
| 20080287470 | Presentation of an Antiviral Pharmaceutical Composition - A new presentation of an antiviral pharmaceutical composition in solution form comprising as an active agent, aciclovir in an amount of about 5% by weight; a solvent in an amount of from about 10 to 20% by weight; a solubilizing agent in an amount of from about 1.5 to 5.0% by weight; a humectant agent in an amount of from about 2 to 10% by weight; an anti-itching agent in an amount of from about 0.05 to 1.0% by weight; an antioxidant agent in an amount of from about 0.1 to 0.5% by weight and demineralized water in an amount of from about 20 to 80% by weight. | 11-20-2008 |
| 20090042915 | PREVENTIVE OR THERAPEUTIC AGENT FOR HERPESVIRUS-RELEATED DISEASE - [Problems] To provide a medicament, particularly a pharmaceutical composition useful for preventing or treating a variety of diseases caused by infection of a virus of the Herpesviridae family. | 02-12-2009 |
| 20090093502 | ENERGY STATUS OF AN INDIVIDUAL BY ENHANCED USAGE OF AN ENDOGENOUS FUEL SOURCE - The present invention relates to a method of improving the energy status of an individual by enhancing the usage of lactate. Improved lactate usage is accomplished through a composition comprising lactate precursors, adrenergic receptor agonists and insulinotropic agents. | 04-09-2009 |
| 20090099215 | Metabolic enhancing properties of norphenephrine and its salts - Norphenephrine and its salts are disclosed which have powerful metabolic enhancing effects in humans via oral administration. The metabolic enhancing properties include positive blood sugar regulation, increased thermogenesis and fat loss, increased anticatabolism/anabolism, decreased appetite, improved mental focus and psychological outlook and increased energy production and anti-fatigue actions. | 04-16-2009 |
| 20090137612 | Treatment with combined use of oxypurines and ascorbate to prevent and mitigate iron-catalized oxidative damage in Alzheimer's disease and other neurodegenerative disorders - A method is provided for the prevention and treatment of selective progressive degeneration within the central nervous system caused by hydroxyl-free or ferryl-free radicals formed by Fenton-type catalyzed reactions between diffusible hydrogen peroxide and localized bivalent iron. The invention embodies unique pharmacologic composition for antioxidant protection by oral supplementation with hypoxanthine conjointly with either sodium L-ascorbate or L-ascorbic acid. The hypoxanthine is provided for its sodium-dependent intestinal absorption and transport for the systemic production of higher antioxidant and iron-chelating uric acid levels. Ascorbate is provided as potent antioxidant to raise body ascorbic acid levels concurrently and to protect against possible deleterious effect from nucleobase or other molecular injury induced by oxidized uric acid as urate anion free radical caused in the antioxidant action of the uric acid. It is contemplated that such oral supplementation conjointly with hypoxanthine and L-ascorbate will support better health and will mitigate the progressive oxidative neuronal damage in Alzheimer's disease, amnestic mild cognitive impairment, Down syndrome, amyotrophic lateral sclerosis, and Parkinson's disease. | 05-28-2009 |
| 20090149481 | PHARMACEUTICAL COMPOSITION AND BEVERAGE COMPOSITION COMPRISING L-ARGININE - A pharmaceutical composition and a beverage composition comprising the following three components (A), (B) and (C): (A) L-arginine or a salt thereof; (B) caffeine or a salt thereof; and (C) at least one substance selected from the group consisting of vitamin C or a derivative thereof, vitamin E or a derivative thereof and folic acid or a derivative thereof. The compositions show an effect of L-arginine even at a low L-arginine content, and therefore can be suitably used for the prevention, amelioration and/or treatment of at least one disease selected from the group consisting of arteriosclerosis, angiectasia, hyperlipemia, climacteric disorder, diabetes, angina pectoris, hypertension, erectile dysfunction, thrombosis, immunodeficiency, dementia, gestosis, respiratory failure and hemorrhoid, in the form of a pharmaceutical preparation or a beverage. | 06-11-2009 |
| 20100041679 | ORAL DIETING COMPOSITION COMPRISING CONJUGATED LINOLEIC ACID AND CAFFEINE - The invention relates to a dieting composition for oral administration, comprising a mixture of conjugated linoleic acid and caffeine as active ingredient and an acceptable support for oral administration. | 02-18-2010 |
| 20100160353 | PHARMACEUTICAL COMPOSITION AND BEVERAGE COMPOSITION COMPRISING L-ARGININE - A pharmaceutical composition and a beverage composition comprising the following three components (A), (B) and (C): (A) L-arginine or a salt thereof; (B) caffeine or a salt thereof; and (C) at least one substance selected from the group consisting of vitamin C or a derivative thereof, vitamin E or a derivative thereof and folic acid or a derivative thereof. The compositions show an effect of L-arginine even at a low L-arginine content, and therefore can be suitably used for the prevention, amelioration and/or treatment of at least one disease selected from the group consisting of arteriosclerosis, angiectasia, hyperlipemia, climacteric disorder, diabetes, angina pectoris, hypertension, erectile dysfunction, thrombosis, immunodeficiency, dementia, gestosis, respiratory failure and hemorrhoid, in the form of a pharmaceutical preparation or a beverage. | 06-24-2010 |
| 20100227874 | REDUCTION OF OXIDATIVE STRESS DAMAGE DURING OR AFTER EXERCISE - Use of at least 25 mg of a polyphenol for the preparation of a product to be consumed before or during exercise for reducing oxidative stress damage during or after exercise. | 09-09-2010 |
| 20110034486 | USE OF PTEROCARPANS AS ACTIVE ANTI-CELLULITE INGREDIENTS - The invention relates to a cosmetic, dermatological or pharmaceutical preparation, containing one, two or more compounds of formula (I) and/or a pharmaceutically acceptable salt of a compound of this type, | 02-10-2011 |
| 20120010225 | PHARMACEUTICAL COMPOSITION - The present invention provides pharmaceutical compositions, which are useful for treatment of depression and the like, and which comprises a compound having an adenosine A | 01-12-2012 |
| 20130018061 | Method for Improving Exercise and Recovery From ExerciseAANM Bashir; RazaAACI OakvilleAACO CAAAGP Bashir; Raza Oakville CAAANM Wissent; CraigAACI OakvilleAACO CAAAGP Wissent; Craig Oakville CA - A method for improving exercise performance and recovery from exercise is provided. The method involves administration of a specific ratio of caffeine and L-theanine. The method is useful for any individual participating in exercise and may be particularly beneficial for individuals accustomed to regular, high caffeine intake. | 01-17-2013 |
| 20130096143 | N-ACYL AMINO ACID DERIVATIVES FOR TREATING SKIN CONDITIONS SUCH AS CELLULITE - The invention relates to small molecules having biological and therapeutic activity. Particularly, the invention relates to small molecules having lipolytic and anti-adipogenic activity. Two examples of such molecules are 4-methyl-2-(octanoylamino) pentanoic acid and N-isopentyloctanamide. The invention further relates to methods of preventing or treating skin conditions such as cellulite using small molecules having lipolytic and anti-adipogenic activity. | 04-18-2013 |
| 20130150382 | NOVEL PHARMACEUTICAL DOSAGE FORMS COMPRISING VALGANCICLOVIR HYDROCHLORIDE - The present invention provides novel solid pharmaceutical dosage forms for oral administration, after being constituted in water. The solid dosage forms comprise a therapeutically effective amount of valganciclovir hydrochloride and a non-hygroscopic organic acid present in an amount sufficient to stabilize the valganciclovir hydrochloride in a predetermined amount of water. The present invention also provides novel liquid pharmaceutical dosage forms for oral administration after constituting the solid pharmaceutical dosage form with water. A non-hygroscopic bulking agent may optionally be included in the above dosage form. These novel pharmaceutical dosage forms are useful in the treatment or control of viruses such as herpes simplex virus and cytomegalovirus. The present invention also provides a method for treating these diseases employing the solid and liquid pharmaceutical dosage forms and a method for preparing these pharmaceutical dosage forms. | 06-13-2013 |
| 20130190333 | Pharmaceutical Combination - A combination comprising as components (a) the compound 3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol, and (b) one or more non-steroidal anti-inflammatory drugs (NSAIDs); a pharmaceutical salt comprising said components; a compound derived from said components; a pharmaceutical formulation and a dosage form comprising said combination, salt, or compound; as well as a method of treating pain, e.g. chronic or acute pain, in a mammal characterized in that components (a) and (b) are administered simultaneously or sequentially to a mammal, wherein component (a) may be administered before or after component (b) and wherein components (a) or (b) are administered to the mammal either via the same or a different pathway of administration. | 07-25-2013 |
| 20130197015 | NOVEL METHOD TO IMPROVE THE SAFETY AND EFFICACY OF CAFFEINE - The present invention relates to methods and compositions for reducing side effects associated with caffeine consumption. The methods comprise administering a Receptor Switcher, such as N-acetyl cysteine, in combination with caffeine. | 08-01-2013 |
| 20130324563 | METHOD OF INTENSIFYING THE PHYSIOLOGICAL ACTION OF CAFFEINE - It is an object of the present invention to provide: a method for safely and effectively enhancing the physiological action of caffeine even from a low intake of caffeine, when utilized various types of a physiological action of a caffeine which involve stimulation of the central nerve to promote mental function; and a composition for improving physiological function, which comprises, as an active ingredient, the caffeine whose physiological action has been enhanced. As a means to solve the above-mentioned object, the physiological action of caffeine is enhanced by combining caffeine with ornithine or a salt thereof. In addition, the ornithine or a salt thereof in an amount equivalent to 0.1 to 100 parts by weight of free ornithine based on 1 part by weight of the caffeine is mixed with caffeine, as an agent for enhancing the physiological action of caffeine, thereby providing a composition for improving a physiological function comprising caffeine as an active ingredient. The improvement of a physiological function by caffeine in the present invention is the improvement of a physiological function by mental fatigue-reducing action, drowsiness-preventing action, or concentration-maintaining action. | 12-05-2013 |
| 20140200230 | COMPOSITIONS AND METHODS FOR INHIBITING REDOX-SENSITIVE GTPASES - The invention provides compositions for inhibiting a redox-sensitive GTPase protein, including a Rho or Rab family GTPase, comprising an effective amount of a redox-sensitive purine compound and an effective amount of a redox agent. The invention further provides methods of inhibiting a redox-sensitive GTPase protein, including a Rho or Rab family GTPase, by administering compositions of the invention. Methods of screening for compounds that inhibit a redox-sensitive GTPase protein, including compounds that target and inhibit Rho or Rab family GTPases, are further provided. | 07-17-2014 |
| 20150011570 | TRANSDERMAL DELIVERY OF BENEFICIAL SUBSTANCES EFFECTED BY A HOSTILE BIOPHYSICAL ENVIRONMENT - The present invention generally relates to the transdermal delivery of substances and, in some embodiments, to the transdermal delivery of beneficial substances by a hostile biophysical environment. In one aspect, various methods for the transdermal delivery of beneficial substances are disclosed. By creating a hostile biophysical environment, beneficial substances may be delivered, according to certain embodiments, through the stratum corneum of the skin into the body. Beneficial substances include, but are not limited to, pharmaceutical agents, drugs, vitamins, co-factors, peptides, dietary supplements, and others. The beneficial effects disclosed include, for instance, relief of pain and inflammation, prevention and healing of ulcers of the skin, relief of headache, improved sexual function and enjoyment, growth of hair on the scalp, improving muscle size and/or function, removing body fat and/or cellulite, treating cancer, treating viral infections and others. A hostile biophysical environment may also be used in conjunction with systems and methods for increasing local blood flow, according to one set of embodiments. For example, by using a nitric oxide donor such as L-arginine, local blood flow may be increased, e.g., by transdermally delivering the nitric oxide precursor. The nitric oxide donor may be the sole cause of increased blood flow, or it may be supplemented with an adjunct such as theophylline. | 01-08-2015 |
| 20150141440 | Pharmaceutical Composition for Headache Relief - A pharmaceutical composition for headache relief combines a vasoconstricting agent, a pain relief agent, and a disposition altering agent for a three-pronged approach to headache or migraine relief. | 05-21-2015 |
| 20170231996 | STABLE EDIBLE SUPERSATURATED CAFFEINE SOLUTIUONS AND METHODS OF MAKING THE SAME | 08-17-2017 |
